: Cord Blood. Investieren in die Zukunft von Morgen.
Cord Blood America. Alte WKN: A0EAGC ISIN: US21839P1075 Symbol: CBAID
First Quarter Revenues Up 74 Percent to $1.5 Million; Gross Profit Increases 132 Percent
LAS VEGAS, May 23, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that revenues for the first quarter of 2011, ended March 31, totaled $1.458 million, up 74 percent compared to revenues of $0.839 million in the same period in 2010.
The Company announced that its gross profit increased to $986,710, up 132 percent compared to gross profit of $423,977 in the same period in 2010 and that the net loss from operations decreased more than one million dollars. Â The total net loss decreased by more than $704,000.
The fiscal year 2011 resultsinclude revenues from the Company''s acquisitions in Germany and Argentina. Â "We are very pleased by these results and believe we are off Â to an excellent start in 2011. Â As we conclude the matters concerning the recent reverse split, which was approved by more than 80 percent of the shareholders who voted their proxy, we believe we will be able to make a strong case to our investors, and potential investors, about our achievements and future business strategies," said Matthew Schissler, co-founder and CEO.
Geduld müssen wir haben was anderes bleibt uns auch nicht übrig.
Klar war doch, dass Cord nun noch keine Gewinne abwirft, also heißt es warten. Vita34 läuft doch auch, warum soll das nicht auch in den USA so sein?
Das Pflänzle braucht Liebe und Vertrauen. Den Split hatten wir nun, wenn die Preise für Nabelschnurblut nun fällt wird die Nachfrage auch steigen, ein Untehmen welches keinen Gewinn erwirstchaftet kann nun mal nicht sonst wo stehen (sind ja nicht in der IT *LOL )
Also zurücklehnen und abwarten.
Einen schönen Vatertag an alle Männer und natürlich auch Frauen ;)
LAS VEGAS, June 1, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that the Company has filed a Form S-1 with the U.S. Securities and Exchange Commission in connection with its Securities Purchase Agreement with Tangiers Investors, L.P., with whom Cord Blood America has an existing Securities Purchase Agreement. Tangiers Investors has agreed to increase its current capitalization of the company.
The modification of the agreement with Tangiers Investors will provide up to $8 million, $5.7 million which is new capital, for Cord Blood America. This agreement coupled with seller financing, will help to conclude one of the LOI's previously disclosed at www.sec.gov.
"We're now in our due diligence phase with the acquisition and look forward to the next phases. Our first quarter results show the fruits of our acquisition strategy with revenues up 74 percent and gross profit up 132 percent. We're excited to continue this strategy and thank our partners for the increased capital and belief in CBAI," stated Matthew Schissler, Founder Chairman and CEO.
The entire Form S-1 filing is available at www.sec.gov .